Download EMEA User Guide for SMEs
Transcript
1.1 Obtaining a marketing authorisation within the European Union Prior to marketing a medicinal product in the EU, a marketing authorisation (product licence) must be obtained. The company responsible for placing the medicinal product on the market (so-called marketing authorisation holder) must be "established" 2 within the EEA (Iceland, Liechtenstein, Norway and the Member States of the European Union). In the EU, there are two types of marketing authorisation: National marketing authorisations issued by the competent authorities of individual Member States. The medicinal product may be put on the market in all Member States that have granted an authorisation for it. or Community marketing authorisation granted by the European Commission, following a positive opinion from the EMEA. This is a single authorisation that allows the medicinal product to be put on the market in all Member States. Approved conditions of use are laid down in the summary of product characteristics 3 (prescribing information for health professionals), the labelling and the package leaflet for users 4 . This user guide will focus on the use of the centralised procedure for obtaining a Community marketing authorisation. Further information on the regulatory routes for obtaining national marketing authorisations, namely the mutual recognition and decentralised procedure, are highlighted in Section 1.1.2 below. Applicants are advised to refer to the Notice to Applicants, Volume 2A and Volume 6A – Procedures for marketing authorisation 5 , for more detailed information. 1.1.1 Community marketing authorisation – the centralised procedure The European Medicines Agency coordinates the existing scientific resources of the Member States in to evaluate and supervise medicinal products for both human and veterinary use throughout the European Union. The EMEA is primarily involved in the centralised procedure for obtaining a Community marketing authorisation. For queries relating to: orphan designation, paediatric investigation plans, pan-European scientific advice, filing an application for marketing authorisation through the centralised procedure, and EudraVigilance, the EMEA is the primary point of contact. If an SME has any doubt about the appropriate point of contact for a particular issue, the SME Office can provide assistance: [email protected] The agency also gives scientific advice to research-based companies in the development stage of new medicinal products (see Section 3.1) and develops guidelines on quality, safety and efficacy testing requirements (see Section 3.2). 2 Being established, here, means having a permanent legal structure (formed in accordance with the law of an EU Member State or other EEA country) that allows the concerned person to assume the duties and responsibilities as well as to perform the tasks laid down by Community law, see Annex II of Chapter I, Vol. 2A (human medicines) or 6A (veterinary medicines) of the Notice to Applicants http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/index.htm . 3 In accordance with Article 11 of Directive 2001/83/EC for human medicines and Article 14 of Directive 2001/82/EC for veterinary medicines. 4 In accordance with Articles 54, 55, 59 and 63 of Directive 2001/83/EC for human medicines and Articles 58-61 for veterinary medicines. 5 Published on the European Commission’s Pharmaceuticals website: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/eudralex_en.htm © EMEA 2009 5/69